LL-Z1271alpha: an interleukin-1beta production inhibitor |
| |
| Authors: | Ichikawa K Inagaki T Kachi-Tonai H Kojima Y Nakamura T Nishida H Ueno Y Binding P Gabel C A Lucas V McNiff P A Kojima N |
| |
| Affiliation: | Exploratory Medicinal Sciences, PGRD, Nagoya Laboratories, Pfizer Pharmaceuticals Inc., 5-Gochi Taketoyo-cho, Chita-gun, Aichi 470-2393, Japan. katsuomi ichikawa@japan.pfizer.com |
| |
| Abstract: | LL-Z1271alpha, a fungal metabolite, dose-dependently inhibited interleukin-1beta (IL-1beta) production in lipopolysaccharide (LPS)-stimulated human whole blood. Oral administration of LL-Z1271alpha to LPS-challenged mice caused significant lowering in the IL-1beta levels in peritoneal cavity. Data presented suggest that LL-Z1271alpha inhibits IL-1beta production by a novel mechanism as the inhibitory activity was not due to effects on caspase-1 (IL-1beta converting enzyme), the ATP-induced release mechanism or a lysosomotrophic effect. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
